Objectives Cisplatin ototoxicity affects 42-88% of treated children. Catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic variants have been associated with ototoxicity, but the findings have been contradictory. The aims of the study were as follows: (a) to investigate these associations in a carefully phenotyped cohort of UK children and (b) to perform a systematic review and meta-analysis.
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Objectives Cisplatin ototoxicity affects 42-88% of treated children. Catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic variants have been associated with ototoxicity, but the findings have been contradictory. The aims of the study were as follows: (a) to investigate these associations in a carefully phenotyped cohort of UK children and (b) to perform a systematic review and meta-analysis.
Methods We recruited 149 children from seven UK centres using a retrospective cohort study design. All participants were clinically phenotyped carefully. Genotyping was performed for one ACYP2 (rs1872328), three TPMT (rs12201199, rs1142345 and rs1800460) and two COMT (rs4646316 and rs9332377) variants.
Results For CTCAE grading, hearing loss was present in 91/120 (75.8%; worst ear) and 79/120 (65.8%; better ear). Using Chang grading, hearing loss was diagnosed in 85/119 (71.4%; worst ear) versus 75/119 (63.0%; better ear). No TPMT or COMT single-nucleotide polymorphisms (SNPs) were associated with ototoxicity. ACYP2 SNP rs1872328 was associated with ototoxicity (P = 0.027; worst ear). Metaanalysis of our data with that reported in previous studies showed the pooled odds ratio (OR) to be statistically significant for both the COMT SNP rs4646316 (OR: 1.50; 95% confidence interval: 1.15-1.95) and the ACYP2 SNP rs1872328 (OR: 5.91; 95% confidence interval: 1.51-23.16).
Conclusion
We showed an association between the ACYP2 polymorphism and cisplatin-induced ototoxicity, but not with the TPMT and COMT. A meta-analysis was statistically significant for both the COMT rs4646316 and the ACYP2 rs1872328 SNPs. Grading the hearing of children with asymmetric hearing loss requires additional clarification. Pharmacogenetics and Genomics 27:213-222 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Cisplatin is a chemotherapeutic agent used to treat solid malignancies in childhood, including in the central nervous system (CNS). Although highly effective, its therapeutic index is narrow. Adverse effects include irreversible bilateral sensorineural hearing loss [1] .
Hearing loss in childhood affects crucial areas of development. Even minimal sensorineural hearing loss can affect both academic ability and overall level of function (behaviour, energy, stress, social support and self-esteem) [2] . It may be of particular importance for children with brain tumours, where a variety of neurotoxicities can occur and significantly combine to impair recovery and lead to worsening disability.
There are established risk factors for the development of cisplatin-related hearing loss including cumulative dose of cisplatin, younger age (especially < 5 years), concomitant (or preceding) radiotherapy to the CNS [3] and exposure to carboplatin in myeloablative doses [1, [4] [5] [6] .
Study populations have often been small (median 67 patients; range: 22-238) and heterogeneous with respect to diagnoses, age, dose of cisplatin, treatment schedules, hearing grading and coadministration of concurrent ototoxic agents and cranial radiotherapy. In addition, there is no consensus on how to define hearing loss, leading to variability in the assessment and grading of ototoxicity.
Despite this, there does also appear to be significant interindividual variability in cisplatin-induced hearing loss. Irreversible hearing loss can occur after a single dose of cisplatin in some individuals, whereas other children do not develop hearing loss even after multiple and high doses of cisplatin [9] . Several studies have identified potential predisposing genetic variants influencing cisplatin-induced hearing loss. Thiopurine methyltransferase (TPMT) and catechol-O-methyltransferase (COMT) [12] (n = 162) risk genotypes were first described in 2009, with TPMT (but not COMT) being replicated in a subsequent cohort [15] (n = 155). However, neither gene was replicated in three additional studies [16, 17] (n = 213, 110, and 38). A meta-analysis of all of the above studies did associate COMT (but not TPMT) with cisplatininduced ototoxicity [17] . Subsequently, another group failed to find an association with either TPMT or COMT [18] (n = 63). There is therefore considerable uncertainty in terms of whether TPMT and/or COMT polymorphisms represent genuine risk factors for cisplatin-induced ototoxicity.
More recently, another genetic variant [ACYP2 (rs1872328)] was identified using a genome-wide association study in 238 children with brain tumours [14] , which was replicated within the original study. An additional study has also recently replicated the association with ACYP2 in patients (n = 156) with osteosarcoma [19] . In the present study, our aim was two-fold: first, to test for an association between variants in the COMT, TPMT and ACYP2 genes and cisplatin-induced hearing loss, in a carefully phenotyped cohort of UK children, and second, to carry out a systematic review and meta-analysis to determine the association with TPMT, COMT and ACYP2 data.
Materials and methods

Study design and criteria
Participants were recruited to the Molecular Genetics of Adverse Drug Reactions in Childhood (MAGIC) study. Ethical approval for this study was granted by the North West 3 Research Ethics Committee (10/H1002/57). For cisplatin, a target recruitment of 400 has been established for a genome-wide association study. This substudy sample size was determined by recruitment achieved at the time that the candidate gene analysis was carried out.
For inclusion in the study, the patients needed to have started cisplatin on or after 1 January 2001 and to have undergone at least one evaluable audiogram following the last dose of cisplatin (post-treatment audiogram).
To be considered evaluable, the audiogram had to fulfil the following criteria: (a) either pure tone audiogram or visual response audiogram in dbHL and (b) tested at 1, 2 and 4 kHz and either 6 or 8 kHz. The exclusion criteria were as follows:
(1) Parent/guardian unwilling to take part (if participant < 16 years at the time of recruitment). 
Consent and data collection
All parents (patient < 16 years) or patients (age ≥ 16 years) provided written informed consent before recruitment to this study. Hearing impairment was assessed on the posttreatment audiogram.
DNA collection and extraction
Patient samples for DNA were collected as whole-blood EDTA samples or salivary samples. DNA collection and extraction for saliva samples have been described previously [20] . EDTA blood samples were stored at − 80°C and following defrosting, genomic DNA was extracted using the Chemagen whole-blood DNA extraction kit on the Chemagic Magnetic Separation Module I according to the manufacturer's protocol (PerkinElmer chemagen Technologie GmbH, Baesweiler, Germany; http://www. chemagen.com).
Genotyping
Genotyping was performed for three TPMT variants (rs12201199, rs1142345 and rs1800460) and two COMT variants (rs4646316 and rs9332377) [12] , and the single-nucleotide polymorphisms (SNPs) rs1872328 for ACYP2 [14] , as described previously [20] . The following Taqman Drug metabolism genotyping assays were used: C_31923406_10 (for rs12201199), C_19567_20 (for rs1142345), C_30634116_20 (for rs1088460), C_29193982_10 (for rs4646316), C_29614343_10 (for rs9332377) and C_11643398_10 (for rs1872328).
Phenotype definition
We graded all audiograms according to CTCAE for COMT and TPMT [12, 21] and assigned Chang grades for ACYP2 [14, 22] For the purpose of our primary analyses, our phenotype was treated as ordinal. First, a univariate multinomial logistic regression model was fitted for each nongenetic factor in turn to identify which nongenetic factors to adjust for in the SNP association analyses. Next, multivariable multinomial logistic regression models were fitted for each SNP in turn. For each SNP, two models were fitted. The first model included covariates to represent all nongenetic factors with a P value of less than 0.25 univariately. Stepwise variable selection was applied to this baseline model to remove any covariates no longer significant in the multivariable model. The final model following variable selection was called the 'baseline model'. The second model (the genetic model) was the same as the baseline model but also included a covariate to represent the SNP. The likelihood ratio test was used to compare the two models and thus assess for statistical significance of the SNP. As five SNPs were tested for association with the outcome of CTCAE grade, a Bonferroni adjustment for five tests was applied to these analyses of association. No adjustment was applied to the test for association between the ACYP2 SNP and Chang grade. In cases of asymmetric hearing loss, the worse ear grade was used as the final ototoxicity grade [14, 16, 22] . To avoid bias arising from this approach, a sensitivity analysis was carried out using the ototoxicity grade of the better ear as the final grade. Further sensitivity analyses of ototoxicity grades were carried out by dichotomizing outcomes in three different ways: CTCAE grade 0 versus 1-4; CTCAE grade 0 versus 2-4; and CTCAE grade 0 versus 3-4. The statistical approach to the sensitivity analyses was the same as that for the ordinal outcome, but logistic regression models were used instead of multinomial logistic regression models.
Systematic review and meta-analysis
A search was performed on 17 March 2016 in Embase and Medline databases using the search strategy and exclusion criteria detailed in Supplementary Table S2 (Supplemental digital content 2, http://links.lww.com/FPC/B198). The paediatric search terms were based on published examples [23] .
Two reviewers (C.B. and A.L.J.) independently screened all papers identified for inclusion. Any conflicts were resolved by discussion (C.B. and A.L.J.). The methodological quality of the papers was assessed using a published quality assessment checklist [24] . The following data were extracted from each study: year of publication, ethnicity of participants, SNPs investigated, outcomes investigated including their definition, sample size and study design. If more than one study investigated associations between the same SNP and outcome combination, data required to carry out a meta-analysis were extracted, including numbers in each genotype group, number of cases and controls per genotype group, odds ratio (OR), SE of OR and confidence interval (CI) for OR.
These data were synthesized using the software package Review Manager 5.3 (The Cochrane Collaboration, 2014). As different papers had carried out analyses assuming different modes of inheritance and because of the variability between studies in how data were reported, it was only possible to carry out a meta-analysis where the allelic OR was calculated (i.e. the OR of developing ototoxicity for the mutant allele vs. the wildtype allele). The statistical method used to estimate a pooled OR across studies was the Mantel-Haenszel random-effects method [25] and heterogeneity was assessed by referring to the I 2 statistic [26, 27] . No formal adjustment for study quality was made in the meta-analyses; however, the results of assessment of methodological quality were considered when exploring potential sources of heterogeneity.
Results
One hundred and forty-nine patients were consented, but data were not available for six. In addition, 23 did not have the required audiograms to allow any grading of ototoxicity and a single patient's data were insufficient to distinguish between Chang grade 1b and 2a. There were 120 evaluable patients for CTCAE and 119 patients for the Chang criteria ( Supplementary Fig. S3 , Supplemental digital content 3, http://links.lww.com/FPC/B199).
The distribution of underlying diagnoses was as follows: medulloblastoma (30.0%; 36/120), hepatoblastoma (12.5% 15/120), osteosarcoma (24.2%; 29/120), neuroblastoma (12.5%; 15/120), other CNS tumours (15.8%; 19/120) and other non-CNS tumours (5.0% 6/120). The self-reported ethnicity was White for 88.3% (106/120) of the patients, Asian (6/120) for 5% and African for 3.3% (4/120); for one child, the ethnicity was Chinese and for three children, the ethnicity was not known.
Clinically, using CTCAE grading, 91/120 (75.8%) patients experienced hearing loss (analysis of worst ear) versus 79/120 (65.8%) patients (better ear). Using Chang grading and considering the worse ear in cases of asymmetrical hearing loss, 85/119 (71.4%) patients experienced hearing loss versus 75/119 (63.0%) considering the better ear. In our study, the number of patients with asymmetric hearing loss, leading to differential grading in each ear, was therefore 12/120 (10.0%) for CTCAE grading and 10/119 (8.4%) for Chang grading.
Genomic quality control results
Four patients were excluded from the analysis after quality control as results for two or more SNPs were missing. All variants had MAF more than 5% and all passed the HW test (P > 0.05). Table 1 shows the demographic details of the 116 children included in the genetic analysis.
Results of univariate analysis
The results of univariate analyses of association with each nongenetic factor are also shown in Table 1 . Of the 98 children in this study who did not receive combined cisplatin and carboplatin therapy, 27 received carboplatin after cisplatin therapy, likely as alternative therapy because of cisplatin-induced nephrotoxicity or ototoxicity. All children in this group also had grade CTCAE 1-4 hearing loss (worse ear), whereas 1/27 did not have hearing loss using Chang criteria (worse ear) and two children did not have hearing loss in the better ear (Chang and CTCAE criteria).
Analysis of COMT and TPMT variants
The summary statistics detailing the frequency of hearing loss for each genetic variant investigated are shown in Table 2 . Clinical factors included in the multivariable analysis (P < 0.25) were as follows: patient age at diagnosis, sex, cranial irradiation, cumulative dose of cisplatin, exposure to vincristine and carboplatin (Table 1) . On applying variable selection to the multivariable model including all these factors, vincristine was removed because of correlation with cranial irradiation (correlation = 0.52). The Bonferroni-corrected likelihood ratio test P-values for the five SNPs are shown in Table 3 . None of the TPMT or COMT SNPs were associated with cisplatin-induced hearing loss (Table 3) . In sensitivity analyses, there were still no significant associations with cisplatin-induced hearing loss for any of the variants using dichotomized outcomes (Supplementary Table S4 
Analysis of ACYP2 variant
The summary statistics detailing the frequency of hearing loss for each genetic variant investigated are shown in Table 2 .
Clinical factors included in the multivariable analysis (P < 0.25) were patient age at diagnosis, sex, cranial irradiation, cumulative dose of cisplatin and exposure to vincristine and carboplatin (Table 1) . ACYP2 SNP rs1872328 was associated with ototoxicity (P = 0.027), where ototoxicity grade was modelled as an ordinal variable with reference to the worse ear grade in cases of asymmetric hearing loss (Table 4) . However, in sensitivity analyses using the better ear grade and ordinal as well as dichotomized outcomes, there was no significant association between the investigated ACYP2 variant and cisplatin-induced hearing loss (Supplementary Tables S7,  Supplemental digital (Table 5) .
Systematic review and meta-analysis
The search strategy identified 256 possibly relevant papers, but after screening for inclusion/exclusion criteria, seven studies were included [12, [14] [15] [16] [17] [18] [19] . The Quorum flow chart detailing the studies identified and included is shown in Supplementary Fig. S10 , Supplemental digital content 10, http://links.lww.com/FPC/B206, with key study information summarized in Table 6 . The results of the methodological quality assessment of the included studies are shown in Supplementary Table S11, Supplemental digital content 11, http://links.lww.com/FPC/B207, with discussion of these results in Supplementary Appendix S12, Supplemental digital content 12, http://links.lww.com/FPC/B208.
It was possible to carry out six different meta-analyses, one each for SNPs rs12201199, rs1800460 and rs1142345 in the TMPT gene, one each for SNPs rs4646316 and rs9332377 in the COMT gene and one for SNP rs1872328 in the ACYP2 gene. For the first five meta-analyses, cases were defined as those with CTCAE grade 2-4, whereas controls were defined as those with CTCAE grade 0. For the sixth meta-analysis, cases were defined as those with Chang grade more than 0, whereas controls were defined as those with Chang grade 0. Although the study by Lanvers-Kaminsky, investigating the rs12201199 and rs9332377 SNPs, used a different method for defining ototoxicity (Muenster classification), it was included in the meta-analyses. However, sensitivity meta-analyses excluding the study by Lanvers-Kaminsky were also carried out for these two SNPs. Forest plots showing the results of the meta-analyses are provided in Fig. 1a-f .
The pooled OR was statistically significant for the associations with the COMT SNP rs4646316 (OR: 1.50; 95% CI: 1.15-1.95) and with the ACYP2 SNP rs1872328 (OR: 5.91; 95% CI: 1.51-23.16). In both cases, the extent of heterogeneity between studies was low (3 and 6%, respectively). For the rs12201199 SNP in the TPMT gene, the pooled OR was not statistically significant (OR: 1.83; 95% CI: 0.89-3.76), but there was a relatively high heterogeneity between studies (I 2 : 59%). Carboplatin Yes refers to patients for whom cisplatin and carboplatin were part of the same treatment protocol. No refers to patients who were not exposed to carboplatin whilst they were also treated with cisplatin. Patients in the latter group may have been switched from cisplatin to carboplatin therapy during their treatment.
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The same was true for the other two TPMT SNPs: rs1142345 0.67-1.95), but again the level of heterogeneity between studies was relatively high (I 2 : 66%). On excluding the study by Lanvers-Kaminsky from the meta-analyses for SNPs rs12201199 and rs9332377, the conclusions remained the Table 2 Summary statistics for genetic data CTCAE grading for COMT, TPMT and ACYP2 CTCAE criteria using worse ear in cases of asymmetric hearing loss COMT, catechol-O-methyltransferase; TPMT, thiopurine methyltransferase. Table 3 Multivariable regression analysis of the association between COMT and TPMT polymorphisms and cisplatin-induced ototoxicity using CTCAE grading as an ordinal outcome Analysis carried out using worse ear grade (in cases of asymmetric hearing loss).
COMT, catechol-O-methyltransferase; TPMT, thiopurine methyltransferase.
same (data not shown), but the level of heterogeneity increased in both cases.
Discussion
Our study highlights the known risk factors for cisplatininduced ototoxicity in children, including increasing cumulative dose of cisplatin [1, 5, 9, 11, 28] , younger age [5, 11, 16] , cranial radiotherapy [4, 13, 29] and exposure to other ototoxic agents such as vincristine [15] . Our study did not detect ethnic origin as a risk factor for hearing loss in patients receiving cisplatin therapy, but this was not our intention as nearly 90% of our study population was White.
Our data did not replicate previous findings that COMT and TPMT variants are risk factors for cisplatin-induced ototoxicity, consistent with several other studies [16] [17] [18] . Heterogeneity between study populations with respect to size, age range, tumour type, cranial radiotherapy, ethnicity, use of potentially otoprotectant therapy (amifostine) and retrospective versus prospective nature of studies are likely to be confounding variables [16, 17] . We addressed these through additional sensitivity analyses, and by using multivariable models, but the conclusions remained the same. Sample size is perhaps the most limiting factor of our study. However, combining our data with previous studies, the pooled OR was statistically significant for the associations with the COMT SNP rs464316 (OR: 1.50; 95% CI: 1.15-1.95; I 2 : 3%), which supports the findings from a previous meta-analysis [17] .
In addition, our study replicated the association between the ACYP2 polymorphism and cisplatin-induced ototoxicity, first identified through a GWAS [14] using ordinal outcome measures (Table 4) . However, the association was lost when restricting our analysis to individuals of White ancestry. This is likely because of the 'loss' of three cases of ototoxicity in GA carriers (data not shown). We were also not able to find the association with dichotomized outcomes on comparing Chang 0 versus more than 0 (Supplementary data section), which was the approach used by Xu et al. [14] to define their discovery cohort. This is likely to be because of several differences between our population and that recruited by Xu et al. [14] , including a higher rate of cranial irradiation, a higher rate of vincristine use (100 vs. 52.2%), a more homogeneous patient group in terms of tumour type and a lower rate of ototoxicity (73 vs. 61% Chang grade > 0, and 45.2 vs. 37% Chang ≥2a) in the latter. Furthermore, more than 50% of the patients in the Xu et al. [14] cohort received the otoprotectant amifostine compared with none of our patients.
Despite these confounders, we followed the analysis of our primary data by carrying out a meta-analysis comparing Chang 0 versus more than 0 in rs1872328 'AG' or 'AA' genotype carriers versus 'GG' carriers as reported in Vos et al. [19] as presented in Fig. 1 . Our pooled OR showed a significant association with this ACYP2 SNP (OR: 5.91; 95% CI: 1.51-23.16), with no heterogeneity observed (I 2 : 0%). Taken collectively, our results suggest that there is a true association between ACYP2 and cisplatin-induced ototoxicity, although further studies are still needed to understand how confounding factors affect this association. Furthermore, functional studies should be carried out to understand the biological plausibility underlying the association as the explanations to date have been speculative.
Patients in this study who received carboplatin and cisplatin combined were not at a higher risk of experiencing hearing loss (Table 2) . This is not an unexpected result. The majority of children who experience hearing loss after carboplatin therapy have also received cisplatin and/ or have received high-dose carboplatin regimens before stem cell transplant [6, 30] . Children who receive standard dose carboplatin alone experience no or only mild hearing loss [31] ; indeed, carboplatin is often used as an alternative to cisplatin once significant ototoxicity has been confirmed.
One of the limitations of this study is that the retrospective study design did not make it feasible to collect detailed dosage data of concomitant medications. In common with many of the previous studies, we did not investigate exposure to aminoglycosides or furosemide in our study. Although ototoxicity is listed in the adverse drug reaction profile in the Summary of Product Characteristics for these medicines independent of cisplatin use, studies that did include some or all of them did not find an association with cisplatin-induced hearing loss [6, 12, 15, 28] .
The level of heterogeneity noted in the systematic review between studies examining all of the TPMT SNPs and COMT rs9332377 was high (I 2 : 47-66%). There are several potential sources for this, including different follow-up periods between studies, different study designs, different ethnic groups represented in the study populations, different treatment regimens and different ages of children recruited. In addition, a factor that has not been discussed previously, but that will impact on all studies investigating ototoxicity, is the grading of asymmetric hearing loss, that is, worse ear versus better ear. UK clinical practice has been to use Brock ototoxicity grading, using the better ear to assign the overall grade. Chang, CTCAE and the new SIOP Boston scale [8] do not stipulate which ear to use. Both Xu et al. [14] and Yang et al. [16] used the worse ear to grade ototoxicity, but it is not clear in other study populations. This variability in how the hearing loss is recorded may partially account for the difficulties in replicating studies.
Conclusion
We have found an association between the ACYP2 polymorphism and cisplatin-induced ototoxicity, although we could not replicate the association with TPMT and COMT variants. Cisplatin is used in a wide variety of tumours, and patient heterogeneity is thus likely to be a confounding factor. However, we were able to show in a meta-analysis that there was an association with the COMT rs464316 SNP and the ACYP2 SNP. Further studies in larger populations would still be worthwhile to define factors that modulate this association, and importantly, we also need to understand the biological basis of the genetic associations. 
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